MAGEA3 and non-small cell lung carcinoma: MG1 has been investigated in clinical trials as an oncolytic cancer vaccine expressing MAGE-A3, which is a known tumor antigen selectively expressed in several types of tumors, such as NSCLC, melanoma, and certain hematological malignancies [89].